Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPM1D | O15297 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15541522 | 0.93 | PPM1D (0.41) | PPM1DMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5009369 | 0.91 | MAPT (0.43) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL516752 | 0.91 | MAPT (0.43) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL12549970 | 0.91 | MAPT (0.43) | MAPTALDH1A1MEN1KMT2ACYP3A4 | |
| SCHEMBL22283634 | 0.91 | MEN1 (0.38) | PPM1DMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL20502795 | 0.91 | MEN1 (0.38) | PPM1DMAPTALDH1A1MEN1KMT2A | |
| SCHEMBL22357286 | 0.84 | SMN1; SMN2 (0.36) | PPM1DALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL19148890 | 0.84 | SMN1; SMN2 (0.36) | PPM1DALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL16167661 | 0.84 | SMN1; SMN2 (0.36) | PPM1DALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL16690752 | 0.82 | MAPT (0.34) | PPM1DMAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10617692-B2 | Pyrrolopyrimidine comprising cyclopentyl substituent | CENTAURUS BIOPHARMA CO. (CN) | 2020-04-14 | — | — | US | disclosed |
| US-10617692-B2 | Pyrrolopyrimidine comprising cyclopentyl substituent | CENTAURUS BIOPHARMA CO. (CN) | 2020-04-14 | — | — | US | disclosed |
| US-10561657-B2 | Pyrrolopyrimidine compound | Centaurus Biophrama Co., Ltd. (CN) | 2020-02-18 | — | — | US | disclosed |
| US-20190201403-A1 | PYRROLOPYRIMIDINE COMPOUND | LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD. (CN) | 2019-07-04 | — | — | US | disclosed |
| US-20190183899-A1 | PYRROLOPYRIMIDINE COMPRISING CYCLOPENTYL SUBSTITUENT | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| US-20190183899-A1 | PYRROLOPYRIMIDINE COMPRISING CYCLOPENTYL SUBSTITUENT | CENTAURUS BIOPHARMA CO., LTD. (CN) | 2019-06-20 | — | — | US | disclosed |
| EP-3235819-A1 | PYRROLOPYRIMIDINE COMPOUND | Centaurus BioPharma Co., Ltd. (CN) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016095805-A1 | PYRROLOPYRIMIDINE COMPOUND | 北京赛林泰医药技术有限公司 | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10561657-B2 | Pyrrolopyrimidine compound | JAK2, JAK1, JAK3 | PPM1D 75/4885MAPT 3008/4885ALDH1A1 1027/4885 |
| US-20190201403-A1 | PYRROLOPYRIMIDINE COMPOUND | JAK2, JAK1, JAK3 | PPM1D 75/4885MAPT 3008/4885ALDH1A1 1027/4885 |
| US-10617692-B2 | Pyrrolopyrimidine comprising cyclopentyl substituent | JAK1, JAK2, JAK3 | PPM1D 120/4885MAPT 2480/4885ALDH1A1 814/4885 |
| US-20190183899-A1 | PYRROLOPYRIMIDINE COMPRISING CYCLOPENTYL SUBSTITUENT | JAK1, JAK2, JAK3 | PPM1D 120/4885MAPT 2480/4885ALDH1A1 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.